Novodiag® Launch, a New Diagnostic Solution for Infectious Diseases
Mobidiag, a Finnish molecular diagnostics company, launches Novodiag ® , a fully automated solution for syndromic and targeted testing of infectious diseases, supporting limitation of antibiotic use.
This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180102005521/en/
Tuomas Tenkanen (Mobidiag CEO) and the fully automated Novodiag® system (Photo: Mobidiag)
The end of 2017 has been marked by a key event for Mobidiag, the launch of the Novodiag® solution at the Finnish Embassy in Paris (France) with the support of M. Ambroise Fayolle, VP of the EIB (European Investment Bank) and Dr. Etienne Ruppé, MCU-PH/Associate Professor, bacteriology department at Bichat hospital (Paris, France).
The new Novodiag® solution allows direct analysis of a patient sample placed in a disposable cartridge and delivers comprehensive results within a few hours. In a time where antibiotic resistance is a major threat for global health, the optimized process offered by Novodiag allows, among other things, to detect antibiotic resistance and limit the systematic use of antibiotics. This instrument allows detection of infectious diseases in a few hours and supports infection management accordingly.
This molecular diagnostic solution offers an easy to use and cost-efficient method, with very limited hands-on-time and without the need for much technical expertise. Novodiag is particularly suitable for low volumes and on demand testing for clinical laboratories.
Novodiag brings the power of molecular diagnostics into routine use for on-demand targeted and syndromic testing, a combination unachieved by other providers says Tuomas Tenkanen, CEO at Mobidiag.
One of our cartridges can also identify dozens of targets, including the majority of bacteria that cause diarrhea, for instance. With quick and reliable results, our fully automated system can support early decision making prior to any treatment delivery and also improve patient care by reducing for example the unnecessary use of antibiotics, a key focus in our product pipeline explains Tuomas Tenkanen.
Zoom on Mobidiag, a committed player in the fight against antibiotic
Mobidiag takes action in infectious disease diagnostics, including antibiotic resistances. There are between twenty five to thirty antibiotic resistant genes. Our solution can, with one single sample, detect large panel of targets. We can then avoid spreading of these resistances in hospital settings, sates Yann Marcy, Director of Mobidiag France.
Learn more about Novodiag.
About Mobidiag Ltd.
Established in 2000, Mobidiag develops and commercializes innovative solutions to advance the diagnosis of infectious diseases and serves the European clinical diagnostics market since 2008. Mobidiag is headquartered in Espoo, Finland, with an R&D center in France and subsidiaries in UK and Sweden.
Combining Amplidiag and Novodiag solutions, Mobidiag offers a comprehensive line of products for fast, reliable and cost-efficient diagnostics. Mobidiag is then able to cover all laboratories requirements no matter their size, throughput and centralized/decentralized organization.
To learn more, visit www.mobidiag.com.
Dorothee Allard, + 33(0)1 55 25 17 13
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
project44 and Gatehouse Logistics Announce Exclusive Partnership17.10.2018 07:00 | Pressemelding
project44 (p44) and Gatehouse Logistics jointly announced today that they have entered into an exclusive, multinational agreement which will provide secure and authorized access to the largest visibility network across North America and Europe. Ultimately, accelerating the ability for both technology providers to deliver visibility solutions across multiple transportation modes and geographies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181017005211/en/ End-to-end supply chain visibility is critical for complex global organizations looking to monitor global operations, increase efficiencies and improve the overall customer experience. This first of its kind multinational partnership provides visibility into key transportation processes, ensuring global organizations can accurately see and proactively respond to all events in their supply chain at the “speed of thought.” Gatehouse Logistics CEO Jesper Bennike commented th
WHOOP, the Human Performance Company, Launches in Europe17.10.2018 07:00 | Pressemelding
WHOOP, the human performance company, is now available to European consumers for the first time. Launched in the US in 2014, WHOOP is now shipping to countries throughout Europe via the WHOOP website. Initial countries include Belgium, Denmark, Finland, France, Germany, Ireland, Italy, the Netherlands, Spain, Sweden and the United Kingdom. Many pro athletes and teams across Europe are already using WHOOP, which was first made available to consumers in the US in 2016. WHOOP was co-founded in 2012 by former Harvard students Will Ahmed, John Capodilupo and Aurelian Nicolae. As captain of Harvard’s D1 squash team, Ahmed, the company's CEO, found that he and his teammates frequently over trained, misinterpreted fitness peaks, and underestimated recovery and sleep, often leading to injury. He became inspired by a simple idea: Humans, especially athletes, could optimize their daily performance if they had a systematic approach to understanding their bodies. The WHOOP Strap 2.0 is a wearable d
Biogen and Samsung Bioepis Announce European Launch of IMRALDI™(adalimumab), Solidifying Leadership in European Anti-TNF Market17.10.2018 06:18 | Pressemelding
Biogen (Nasdaq:BIIB) and Samsung Bioepis Co., Ltd. today announced the European launch of IMRALDI™ (adalimumab), a biosimilar referencing HUMIRA®. Starting today, IMRALDI™ will begin launching in major markets across Europe. The launch of IMRALDI™ marks a significant milestone for Biogen and Samsung Bioepis, as the adalimumab product is the third anti-TNF biosimilar developed by Samsung Bioepis to be commercialized by Biogen across Europe. BENEPALI™ (etanercept) and FLIXABI™ (infliximab) were approved in 2016, and have approximately 100,000 patients currently under treatment with more than 6 million doses administered across 25 and 14 countries, respectively.ii “We look forward to increasing patient access to this important medicine by leveraging our industry-leading position in the European anti-TNF market,” said Ian Henshaw, Head of Biogen’s Biosimilars Unit. “The launch of IMRALDI marks what we believe to be a landmark moment for Biogen and Samsung Bioepis and for European healthcar
Durabook Delivers World’s Toughest Semi-Rugged Computer17.10.2018 06:00 | Pressemelding
Durabook, the global brand fully owned by Twinhead International Corporation, has today introduced the most durable semi-rugged computer ever created. The Durabook S14I greatly exceeds all existing devices in its class in both drop height and IP ratings. Built with 8th generation Intel® CPU and a wide selection of I/O options, the S14I is ideal for demanding working environments of public safety, government, military and field service. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181016006151/en/ Durabook S14I Features Class-Leading Drop Height and IP Ratings along with 8th Generation Intel CPU Power (Photo: Business Wire) “As the definition of the modern workplace expands, the line between what is office and what is field are often becoming blended” said Fred Kao, CEO of Twinhead. “So we are blending the line between what is a semi-rugged and what is a fully-rugged. Under the form factor of a traditional semi-rugged lapto
DIA Drives Debates and Solutions at the Crossroads of Healthcare17.10.2018 06:00 | Pressemelding
DIA, founded as the Drug Information Association, announced three keynote speakers for the upcoming DIA Europe 2019 annual meeting: Dave deBronkart, ‘e-Patient Dave’; Hans Lehrach, Director at the Max Planck Institute for Molecular Genetics; and Kristel Van der Elst, CEO, The Global Foresight Group. The diversity of experience brought by these three leaders is reflective of the meeting mission to ensure industry, payers, patients, and regulators all have an equal voice in the debates advancing regulatory science and access to healthcare. These keynote speakers will join 300 speakers in more than 80 sessions, across seven thought leadership streams to drive collaborative answers in medicines development and access to healthcare. Highlights from sessions include Guido Rasi, Executive Director, EMA, will present first look strategies for 2021-2025 during the European Regulatory Town Hall and Niklas Hedberg, Chair EUnetHTA Executive Board, will feature case studies of Real World Evidence i
SailPoint’s Latest SaaS Release Makes Security and Compliance Accessible to All Enterprises17.10.2018 05:01 | Pressemelding
SailPoint Technologies Holdings, Inc. (NYSE: SAIL), the leader in enterprise identity governance, unveiled a series of new innovations in IdentityNow, the industry’s most comprehensive SaaS identity governance platform. Enhancements have been made with an eye towards both closing security and compliance gaps and simplifying identity implementations for organizations who may not have dedicated identity teams and resources. New in IdentityNow is the Dynamic Discovery Engine, an innovation that allows users to easily and quickly create policies, access reviews, dashboards and reporting. As a result, IdentityNow customers are better able to address the mounting security and compliance challenges that all enterprises face today. “When we started our identity governance journey, a key requirement for us was the ability to automate identity processes where we could, while improving our audit and compliance track record,” said Michael Boucher, Sr. Director, Information Risk Management, FTD. “W